A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA ...

Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...

In the 1970s, scientists knew that some viruses and chemicals caused cancer, but they didn’t know how. Arnold Levine, a biologist currently at the Institute for Advanced Study researched DNA viruses ...

The tumor suppressor protein p53 is mutated in more than half of all human cancers. Several drugs that potentially can restore mutant p53 to its normal cancer-killing function are in clinical ...

Figure 8: Regulation of ALDH3A1 and NECTIN4 by p53. Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney Kimmel ...

Researchers have discovered that aneuploidy drives gain-of-function phenotypes in cells expressing mutant p53. Their report has implications for developing therapies targeting mutant p53. The tumor ...

Phase 0/1 of positron emission tomography (PET) imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with non-small cell lung cancer (NSCLC). Comparison of the tumor mutation burden ...

The p53 tumor suppressor protein is encoded by TP53, the most frequently mutated gene in cancer. A review article published in Nature Reviews Clinical Oncology by Professor Klas G Wiman and colleagues ...

Cancer biologist Scott Lowe says the p53 discovery came as a complete surprise and suggests a new way to think about treating cancer. More than half of all cancers have mutations in a gene called p53.

Since its discovery by Arnold Levine in 1979, the tumor protein p53 has transformed the field of cancer research. p53 signaling plays a key role in regulating the cell cycle, maintaining genome ...